Technical Articles

In the complex landscape of lymph system malignancies, identifying highly specific tumor-associated antigens is crucial for developing effective immunotherapies.

CD30 (TNFRSF8) is a member of the tumor necrosis factor receptor superfamily and a type I transmembrane protein. Under normal physiological conditions, CD30 is only expressed at low levels on the surface of activated T lymphocytes, B lymphocytes, and natural killer cells.

CD30, also known as TNFRSF8, is an important member of the tumor necrosis factor receptor superfamily. As a type I transmembrane protein, its expression is highly restricted in normal tissues, primarily occurring in some activated T and B lymphocytes.

In the human immune system, natural killer cells (NK cells) are a powerful "guard" that can quickly identify and eliminate abnormal cells, including tumor cells. However, in the fight against tumors, NK cells sometimes encounter "cunning" opponents. Recently, a scientific study revealed the key role of the molecule CD48 in tumor cell immune escape, bringing new hope for lymphoma treatment.

In the big family of cancer, lymphoma is a complex and huge existence. It originates from the lymphatic hematopoietic system and covers more than 70 different subtypes, collectively referred to as the "lymphoma family".